Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

NCT02095132 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02095132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02095132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
March 28, 2014
Completion date
June 30, 2023
Enrollment
76 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system embryonal tumor with rhabdoid features, central nervous system embryonal tumor, not otherwise specified, central nervous system ganglioneuroblastoma, embryonal tumor with multilayered rosettes, c19mc-altered, pineoblastoma, primary central nervous system neoplasm, recurrent childhood central nervous system embryonal neoplasm, recurrent malignant solid neoplasm, recurrent medulloblastoma, recurrent neuroblastoma, recurrent rhabdomyosarcoma, refractory malignant solid neoplasm, refractory medulloblastoma, refractory neuroblastoma, refractory rhabdomyosarcoma